In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...
Ego Pharmaceuticals improved assay efficiency, reduced solvent use, and enhanced UV/Vis precision through automated ...
Xenon Pharmaceuticals Inc.’s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory ...
Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic?range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results